Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea, Hong Kong, Taiwan, Japan and Australia: an observational, descriptive study [PDF]
, 2020 Objective: To measure the paediatric user and prescription prevalence in inpatient and ambulatory settings in South Korea, Hong Kong, Taiwan, Japan and Australia by age and gender.
Brauer, R +9 more
core
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series [PDF]
, 2011 Background: Acute liver injury (ALI) induced by paracetamol overdose is a well known cause of emergency hospital admission and death. However, there is debate regarding the risk of ALI after therapeutic dosages of the drug.
A Escorsell +59 more
core +5 more sources
European Respiratory Review, 2010 It has been shown that mucus hypersecretion is associated with greater susceptibility for chronic obstructive pulmonary disease (COPD), excess forced expiratory volume in 1 s decline, hospitalisations and excess mortality. The effects of mucoactive drugs
M. Decramer, W. Janssens
doaj
European Respiratory Review, 2010 Mucus hypersecretion is a clinical feature of severe respiratory diseases such as asthma, cystic fibrosis and chronic obstructive pulmonary disease.
R. Balsamo, L. Lanata, C. G. Egan
doaj
Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease [PDF]
, 2012 Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity globally, and its development is mainly associated with tobacco/biomass smoke-induced oxidative stress.
Aaron +182 more
core +1 more source
Risk assessment of “other substances” - L-cysteine and L-cystine. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety [PDF]
, 2015 The Norwegian Scientific Committee for Food Safety (VKM) has, at the request of the Norwegian Food Safety Authority, assessed the risk of specified doses of L-cysteine and L-cystine in food supplements. VKM concludes that: • In adolescents (14 to
Frøyland, Livar +7 more
core +3 more sources
Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis
International Journal of COPD, 2017 Zheng Zeng,1 Dan Yang,2 Xiaoling Huang,3 Zhenliang Xiao4 1Respiratory Medicine, Southwest Medical University, Luzhou, Sichuan, People’s Republic of China; 2Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People ...
Zeng Z, Yang D, Huang X, Xiao ZL
doaj
Pharmacotherapies for COPD [PDF]
, 2013 This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use.
Ejiofor, Stanley, Turner, Alice M
core +3 more sources
Determinação do prazo de validade do medicamento carbocisteína xarope através do método de Arrhenius [PDF]
, 2007 Carbocysteine is a mucolytic agent in adjunctive therapy of respiratory tract infections. The pharmaceutical industry is responsible for quality, safety and efficiency of the product during its shelf life.
Brum Junior, Liberato +4 more
core +4 more sources
Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine [PDF]
, 2008 S-carboxymethylcysteine (S-CMC) is a mucolytic agent that can prevent respiratory infection by decreasing the attachment of respiratory pathogens to human pharyngeal epithelial cells (HPECs).
Ahmed, K. +7 more
core +1 more source